Literature DB >> 34507949

Self-Renewing Islet TCF1+ CD8 T Cells Undergo IL-27-Controlled Differentiation to Become TCF1- Terminal Effectors during the Progression of Type 1 Diabetes.

Ashley E Ciecko1, David M Schauder1,2, Bardees Foda3,4,5, Galina Petrova3, Moujtaba Y Kasmani1,2, Robert Burns2, Chien-Wei Lin6, William R Drobyski1,7, Weiguo Cui1,2, Yi-Guang Chen8,3,4.   

Abstract

In type 1 diabetes (T1D) autoreactive CD8 T cells infiltrate pancreatic islets and destroy insulin-producing β cells. Progression to T1D onset is a chronic process, which suggests that the effector activity of β-cell autoreactive CD8 T cells needs to be maintained throughout the course of disease development. The mechanism that sustains diabetogenic CD8 T cell effectors during the course of T1D progression has not been completely defined. Here we used single-cell RNA sequencing to gain further insight into the phenotypic complexity of islet-infiltrating CD8 T cells in NOD mice. We identified two functionally distinct subsets of activated CD8 T cells, CD44highTCF1+CXCR6- and CD44highTCF1-CXCR6+, in islets of prediabetic NOD mice. Compared with CD44highTCF1+CXCR6- CD8 T cells, the CD44highTCF1-CXCR6+ subset expressed higher levels of inhibitory and cytotoxic molecules and was more prone to apoptosis. Adoptive cell transfer experiments revealed that CD44highTCF1+CXCR6- CD8 T cells, through continuous generation of the CD44highTCF1-CXCR6+ subset, were more capable than the latter population to promote insulitis and the development of T1D. We further showed that direct IL-27 signaling in CD8 T cells promoted the generation of terminal effectors from the CD44highTCF1+CXCR6- population. These results indicate that islet CD44highTCF1+CXCR6- CD8 T cells are a progenitor-like subset with self-renewing capacity, and, under an IL-27-controlled mechanism, they differentiate into the CD44highTCF1-CXCR6+ terminal effector population. Our study provides new insight into the sustainability of the CD8 T cell response in the pathogenesis of T1D.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34507949      PMCID: PMC8492517          DOI: 10.4049/jimmunol.2100362

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  88 in total

1.  IL-6, in synergy with IL-7 or IL-15, stimulates TCR-independent proliferation and functional differentiation of CD8+ T lymphocytes.

Authors:  Julien Gagnon; Sheela Ramanathan; Chantal Leblanc; Alexandre Cloutier; Patrick P McDonald; Subburaj Ilangumaran
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

2.  IL-27 is required for shaping the magnitude, affinity distribution, and memory of T cells responding to subunit immunization.

Authors:  Nathan D Pennock; Laurent Gapin; Ross M Kedl
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

3.  TCR bias of in vivo expanded T cells in pancreatic islets and spleen at the onset in human type 1 diabetes.

Authors:  Eva Codina-Busqueta; Erika Scholz; Pau M Muñoz-Torres; Carme Roura-Mir; Manuela Costa; Cristina Xufré; Raquel Planas; Marta Vives-Pi; Dolores Jaraquemada; Mercè Martí
Journal:  J Immunol       Date:  2011-02-16       Impact factor: 5.422

4.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells.

Authors:  Stefan Pflanz; Jackie C Timans; Jeanne Cheung; Rency Rosales; Holger Kanzler; Jonathan Gilbert; Linda Hibbert; Tatyana Churakova; Marilyn Travis; Elena Vaisberg; Wendy M Blumenschein; Jeanine D Mattson; Janet L Wagner; Wayne To; Sandra Zurawski; Terrill K McClanahan; Daniel M Gorman; J Fernando Bazan; Rene de Waal Malefyt; Donna Rennick; Robert A Kastelein
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

5.  Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes.

Authors:  L S Wicker; E H Leiter; J A Todd; R J Renjilian; E Peterson; P A Fischer; P L Podolin; M Zijlstra; R Jaenisch; L B Peterson
Journal:  Diabetes       Date:  1994-03       Impact factor: 9.461

6.  Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant.

Authors:  D V Serreze; E H Leiter; G J Christianson; D Greiner; D C Roopenian
Journal:  Diabetes       Date:  1994-03       Impact factor: 9.461

7.  Suppressor of cytokine signaling 3 regulates CD8 T-cell proliferation by inhibition of interleukins 6 and 27.

Authors:  Christine Brender; Gillian M Tannahill; Brendan J Jenkins; Joel Fletcher; Ruth Columbus; Christiaan J M Saris; Matthias Ernst; Nicos A Nicola; Douglas J Hilton; Warren S Alexander; Robyn Starr
Journal:  Blood       Date:  2007-07-03       Impact factor: 22.113

Review 8.  TCF1 in T cell immunity: a broadened frontier.

Authors:  Xudong Zhao; Qiang Shan; Hai-Hui Xue
Journal:  Nat Rev Immunol       Date:  2021-06-14       Impact factor: 53.106

9.  Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers.

Authors:  Suna Onengut-Gumuscu; Wei-Min Chen; Oliver Burren; Nick J Cooper; Aaron R Quinlan; Josyf C Mychaleckyj; Emily Farber; Jessica K Bonnie; Michal Szpak; Ellen Schofield; Premanand Achuthan; Hui Guo; Mary D Fortune; Helen Stevens; Neil M Walker; Lucas D Ward; Anshul Kundaje; Manolis Kellis; Mark J Daly; Jeffrey C Barrett; Jason D Cooper; Panos Deloukas; John A Todd; Chris Wallace; Patrick Concannon; Stephen S Rich
Journal:  Nat Genet       Date:  2015-03-09       Impact factor: 38.330

10.  Single-cell RNA sequencing of murine islets shows high cellular complexity at all stages of autoimmune diabetes.

Authors:  Pavel N Zakharov; Hao Hu; Xiaoxiao Wan; Emil R Unanue
Journal:  J Exp Med       Date:  2020-06-01       Impact factor: 14.307

View more
  1 in total

1.  Autoreactive CD8 T cells in NOD mice exhibit phenotypic heterogeneity but restricted TCR gene usage.

Authors:  Moujtaba Y Kasmani; Ashley E Ciecko; Ashley K Brown; Galina Petrova; Jack Gorski; Yi-Guang Chen; Weiguo Cui
Journal:  Life Sci Alliance       Date:  2022-06-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.